NASDAQ:GRFS Grifols (GRFS) Stock Price, News & Analysis $7.17 -0.20 (-2.71%) Closing price 04:00 PM EasternExtended Trading$7.18 +0.01 (+0.14%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Grifols Stock (NASDAQ:GRFS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Grifols alerts:Sign Up Key Stats Today's Range$7.15▼$7.3650-Day Range$7.17▼$8.2552-Week Range$6.96▼$9.90Volume439,512 shsAverage Volume632,641 shsMarket Capitalization$4.88 billionP/E Ratio37.74Dividend Yield1.26%Price Target$10.00Consensus RatingReduce Company Overview Grifols S.A. is a global healthcare company based in Barcelona, Spain, and is listed on Nasdaq under the symbol GRFS. Founded in 1909, the company is primarily focused on developing, manufacturing and supplying plasma-derived medicines and other healthcare products. Its principal therapies include immunoglobulins, albumin, alpha-1 antitrypsin and coagulation factors, which are used to treat immune deficiencies, respiratory disorders, bleeding conditions and other serious diseases. Grifols operates a network of plasma donation centers, mainly in the United States and Europe, to collect the source plasma used in its medicines. Grifols also provides diagnostic solutions, including instruments and reagents used in blood typing, transfusion medicine and laboratory testing. In addition, the company offers hospital pharmacy products and services. Its operations and products serve healthcare providers and patients in numerous markets across North America, Europe and other international regions.AI Generated. May Contain Errors. Read More Grifols Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreGRFS MarketRank™: 4.445838837515 of 5 starsGrifols scored higher than 89% of companies evaluated by MarketBeat, and ranked 42nd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingGrifols has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialGrifols has a consensus price target of $10.00, representing about 39.5% upside from its current price of $7.17.Amount of Analyst CoverageGrifols has only been the subject of 1 research reports in the past 90 days.Read more about Grifols' stock forecast and price target. Earnings and Valuation5.0 / 5Proj. Earnings Growth24.07% Earnings GrowthEarnings for Grifols are expected to grow by 24.07% in the coming year, from $1.08 to $1.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Grifols is 37.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.65.Price to Earnings Ratio vs. SectorThe P/E ratio of Grifols is 37.74, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 193.55.Price to Earnings Growth RatioGrifols has a PEG Ratio of 0.27. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioGrifols has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Grifols' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.03% of the float of Grifols has been sold short.Short Interest Ratio / Days to CoverGrifols has a short interest ratio ("days to cover") of 8.66.Change versus previous monthShort interest in Grifols has recently increased by 105.05%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldGrifols pays a meaningful dividend of 1.16%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGrifols does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Grifols is 47.37%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Grifols will have a dividend payout ratio of 6.72% next year. This indicates that Grifols will be able to sustain or increase its dividend.Read more about Grifols' dividend. News and Social Media1.9 / 5News Sentiment0.05 News SentimentGrifols has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Grifols this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Grifols insiders have not sold or bought any company stock.Percentage Held by Insiders0.19% of the stock of Grifols is held by insiders.Percentage Held by InstitutionsGrifols has minimal institutional ownership at this time.Read more about Grifols' insider trading history. Receive GRFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRFS Stock News HeadlinesBridgeBio Pharma (NASDAQ:BBIO) versus Grifols (NASDAQ:GRFS) Head-To-Head AnalysisOctober 12 at 5:29 AM | americanbankingnews.comGrifols (NASDAQ:GRFS) Stock Rating Cut to "Hold" at Wall Street ZenOctober 10 at 1:19 AM | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 13 at 1:00 AM | Profits Run (Ad)Are options traders betting on a big move in Grifols stock?October 8, 2026 | msn.comGrifols says Canada plasma license suspension has no impactSeptember 24, 2026 | reuters.comGRFS - Grifols, S.A.September 17, 2026 | seekingalpha.comGrifols: Better Plasma Economics Can Unlock A Discounted EquitySeptember 16, 2026 | seekingalpha.comGrifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin DeficiencyAugust 10, 2026 | markets.businessinsider.comSee More Headlines GRFS Stock Analysis - Frequently Asked Questions How have GRFS shares performed this year? Grifols' stock was trading at $9.35 on January 1st, 2026. Since then, GRFS stock has decreased by 23.3% and is now trading at $7.17. How were Grifols' earnings last quarter? Grifols, S.A. (NASDAQ:GRFS) issued its quarterly earnings results on Tuesday, May, 4th. The biotechnology company reported $0.21 earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by $0.01. The biotechnology company had revenue of $1.43 billion for the quarter. Grifols had a trailing twelve-month return on equity of 6.21% and a net margin of 5.54%. When did Grifols' stock split? Shares of Grifols split on the morning of Monday, January 4th 2016.The 2-1 split was announced on Thursday, December 3rd 2015. The newly minted shares were distributed to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Grifols have any subsidiaries? Grifols subsidiaries include Biotest US Corporation, Haema AG, Goetech LLC (D/B/A Medkeeper), Kiro Robotics, Progenika Biopharma, Araclon Biotech, Talecris Biotherapeutics, and others. Who are Grifols' major shareholders? Grifols' top institutional investors include Financial Symmetry Inc, GAMMA Investing LLC and Versant Capital Management Inc. How do I buy shares of Grifols? Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Grifols own? Based on aggregate information from My MarketBeat watchlists, some other companies that Grifols investors own include Immunovant (IMVT), NVIDIA (NVDA), Gilead Sciences (GILD), Tesla (TSLA), Boeing (BA), Intel (INTC) and Johnson & Johnson (JNJ). Company Calendar Last Earnings5/04/2021Today10/13/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 GRFS's financial health is in the Yellow zone, according to TradeSmith. GRFS has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GRFS CIK1438569 Webwww.grifols.com Phone(493) 571-0221Fax34-93-571-0267Employees25,247Year Founded1909Price Target and Rating Average Price Target for Grifols$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+39.5%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.19 Trailing P/E Ratio37.74 Forward P/E Ratio6.64 P/E Growth0.27Net Income$454.82 million Net Margins5.54% Pretax Margin8.18% Return on Equity6.21% Return on Assets2.39% Debt Debt-to-Equity Ratio1.10 Current Ratio2.37 Quick Ratio0.81 Sales & Book Value Annual Sales$8.51 billion Price / Sales0.57 Cash Flow$1.38 per share Price / Cash Flow5.20 Book Value$12.64 per share Price / Book0.57Miscellaneous Outstanding Shares680,580,000Free Float679,282,000Market Cap$4.88 billion OptionableOptionable Beta0.70 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:GRFS) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
